Sarepta, Myonexus Collaborating to Advance Gene Therapies for LGMD – Muscular Dystrophy News
Muscular Dystrophy News |
Sarepta, Myonexus Collaborating to Advance Gene Therapies for LGMD
Muscular Dystrophy News Sarepta Therapeutics has established an exclusive collaboration agreement with Myonexus Therapeutics to develop five new therapies targeting various forms of limb-girdle muscular dystrophy (LGMD). These include three clinical and two preclinical stage … |
